
    
      This is a single center, randomised, double-blind, active comparator controlled, three-period
      cross-over, single dose trial in subjects with type 1 diabetes mellitus.

      Each subject will be randomly allocated to a sequence of three treatments:(i) simultaneous
      administrations of BioChaperone速 pramlintide human insulin (BC Pram Ins) and placebo, (ii)
      simultaneous injections of pramlintide (Symlin速) and human insulin (Humulin速) and (iii)
      simultaneous injections of insulin lispro (Humalog速) and placebo.

      Subjects will come in a fasted state to the clinical trial centre in the morning, meal test
      procedures will be performed and subjects will stay at the clinical trial centre until the
      post-dose follow-up period has been terminated.
    
  